Parametric contrast‑enhanced ultrasound as an early predictor of radiation‑based therapeutic response for lymph node metastases of nasopharyngeal carcinoma

Ye,Zhimin; Huang,Pintong; Zhou,Xiaofeng; Huang,Qian; Hu,Qiongge; Shui,Yongjie; Shen,Li; Lai,Enyin; Wei,Qichun

doi:10.3892/mco.2014.331

Parametric contrast‑enhanced ultrasound as an early predictor of radiation‑based therapeutic response for lymph node metastases of nasopharyngeal carcinoma

Authors:
- Zhimin Ye
- Pintong Huang
- Xiaofeng Zhou
- Qian Huang
- Qiongge Hu
- Yongjie Shui
- Li Shen
- Enyin Lai
- Qichun Wei
View Affiliations

Affiliations: Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, P.R. China, Department of Ultrasound, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, P.R. China, Department of Physiology, Zhejiang University School of Medicine, Hangzhou 310058, P.R. China
Published online on: June 27, 2014 https://doi.org/10.3892/mco.2014.331
Pages: 666-672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a common type of cancer in South East Asia with peculiar epidemiology, pathology, clinical behavior and response to treatment characteristics. To the best of our knowledge, this is the first study to investigate the use of a contrast‑enhanced ultrasound (CEUS) as a predictor for the therapeutic response in lymph node metastases of NPC patients treated with radiation‑based therapy. Sixty‑seven NPC patients with lymph node metastases underwent the lymph nodes CEUS examination twice; pre‑ and in‑treatment (at the 5th fraction radiotherapy), respectively. The CEUS parameters were acquired through Qontrast_4.0 software and mainly included peak intensity (PI) and time to peak (TTP). The response assessment at the lymph nodes revealed a complete response (CR) in 48 patients and partial response (PR) in 19 patients. There was a significant difference in pre‑treatment PI (PIpre) between the patients who showed CR or PR, but the predicted sensitivity and specificity of PIpre was low. The mean in‑treatment PI (PIin) value of the lymph nodes that achieved a CR was 34.24±3.78%, which was significantly higher than the PIin value for PR, 25.62±2.30% (P<0.001). Furthermore, the PIratio, a PI‑quotient, was calculated by dividing the PIin by the corresponding PIpre. The higher PIratio was also observed in CR lymph nodes (0.81±0.01 vs. 0.66±0.01; P=0.001), and the mean change in PI (PIΔ; PIΔ = PIpre‑PIin) was smaller in the patients with CR nodes compared to the patients with PR nodes (7.79±3.28 vs. 13.77±1.90%; P=0.000). No difference was observed in TTPpre or TTPin between the CR or PR lymph nodes patients. A receiver operating characteristic curve was constructed to assess the accuracy of the parameters for the prediction of the therapeutic responses. The sensitivity and specificity of PIin in predicting the therapeutic response was 94.3 and 88.2%, and the corresponding figures of the PIratio were 92.5 and 83.8%, respectively. The CEUS parameters during the early course of radiation‑based therapy, PIin and PIratio, are associated with the therapeutic response of NPC lymph node metastases, with a high predicted sensitivity and specificity, thus yielding the conceivable predictors with the potential to individualize treatment.

View Figures

View References

1	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
2	Razak AR, Siu LL, Liu FF, Ito E, O‘Sullivan B and Chan K: Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 46:1967–1978. 2010. View Article : Google Scholar
3	Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar
4	Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X and Chang AY: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 23:3568–3576. 2005. View Article : Google Scholar : PubMed/NCBI
5	Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O‘sullivan B, Xu SL, Pang ES, Sze WM, Leung TW, Kwan WH, Chan PT, Liu XF, Tan EH, Sham JS, Siu L and Lau WH: Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 66:142–151. 2006. View Article : Google Scholar
6	Cao Y, Popovtzer A, Li D, Chepeha DB, Moyer JS, Prince ME, Worden F, Teknos T, Bradford C, Mukherji SK and Eisbruch A: Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys. 72:1287–1290. 2008.PubMed/NCBI
7	Korpanty G, Carbon JG, Grayburn PA, Fleming JB and Brekken RA: Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 13:323–330. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chen JJ, Fu SY, Chiang CS, Hong JH and Yeh CK: A preclinical study to explore vasculature differences between primary and recurrent tumors using ultrasound Doppler imaging. Ultrasound Med Biol. 39:860–869. 2013. View Article : Google Scholar : PubMed/NCBI
9	Yankeelov TE, Niermann KJ, Huamani J, Kim DW, Quarles CC, Fleischer AC, Hallahan DE, Price RR and Gore JC: Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med. 25:487–497. 2006.
10	Beaton C, Cochlin D and Kumar N: Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions. Eur J Surg Oncol. 36:43–46. 2010. View Article : Google Scholar
11	Ridolfi F, Abbattista T, Busilacchi P and Brunelli E: Contrast-enhanced ultrasound evaluation of hepatic microvascular changes in liver diseases. World J Gastroenterol. 18:5225–5230. 2012.PubMed/NCBI
12	Rissanen TT, Korpisalo P, Karvinen H, Liimatainen T, Laidinen S, Gröhn OH and Ylä-Herttuala S: High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC Cardiovasc Imaging. 1:83–91. 2008. View Article : Google Scholar : PubMed/NCBI
13	Badea AF, Tamas-Szora A, Clichici S, Socaciu M, Tăbăran AF, Băciut G, Cătoi C, Mureşan A, Buruian M and Badea R: Contrast enhanced ultrasonography (CEUS) in the characterization of tumor microcirculation. Validation of the procedure in the animal experimental model. Med Ultrason. 15:85–94. 2013. View Article : Google Scholar
14	Shah JP, Ang K, Baatenburg De Jong RJ, et al: Head and neck. AJCC Cancer Staging Manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: 7th edition. Springer; New York: pp. 21–100. 2010
15	Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H and Arvind AS: Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 1:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ang J, Hu L, Huang PT, Wu JX, Huang LN, Cao CH, Zheng YX and Chen L: Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol. 18:7026–7032. 2012. View Article : Google Scholar : PubMed/NCBI
17	Moschouris H, Malagari K, Marinis A, Kornezos I, Stamatiou K, Nikas G, Papadaki MG and Gkoutzios P: Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography. World J Radiol. 4:379–386. 2012. View Article : Google Scholar
18	Chawla S, Kim S, Dougherty L, Wang S, Loevner LA, Quon H and Poptani H: Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol. 200:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
19	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
20	Shukla-Dave A, Lee NY, Jansen JF, Thaler HT, Stambuk HE, Fury MG, Patel SG, Moreira AL, Sherman E, Karimi S, Wang Y, Kraus D, Shah JP, Pfister DG and Koutcher JA: Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int J Radiat Oncol Biol Phys. 82:1837–1844. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kim S, Loevner LA, Quon H, Kilger A, Sherman E, Weinstein G, Chalian A and Poptani H: Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 31:262–268. 2010. View Article : Google Scholar : PubMed/NCBI
22	Knieling F, Waldner MJ, Goertz RS, Zopf S, Wildner D, Neurath MF, Bernatik T and Strobel D: Early response to anti-tumoral treatment in hepatocellular carcinoma - can quantitative contrast-enhanced ultrasound predict outcome? Ultraschall Med. 34:38–46. 2013.PubMed/NCBI
23	Schirin-Sokhan R, Winograd R, Roderburg C, Bubenzer J, do Ó NC, Guggenberger D, Hecker H, Trautwein C and Tischendorf JJ: Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol. 18:541–545. 2012. View Article : Google Scholar : PubMed/NCBI